CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.

Abstract

BACKGROUND:

Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology of combinations is needed to improve on the benefit of immune checkpoint inhibitors (ICI).

METHODS:

Using a BRAFV600E-driven murine melanoma model, we tested the immunogenicity of HSV/BRAFi in immunocompetent C57BL mice. In addition to standard FACS analysis, we used the 'Timer of Cell Kinetics and Activity' system, which can analyze the temporal dynamics of different T cell subsets. This immune data was used to inform the selection of ICI for triple combination therapy, the effects of which were then further characterized using transcriptomics.

RESULTS:

Adding BRAFi treatment to HSV improved anti-tumor effects in vivo but not in vitro. Immune characterization showed HSV or dual therapy led to fewer intratumoral Treg, although with a more activated phenotype, together with more effector CD8 +T cells. Tocky analysis further showed that HSV/BRAFi dual treatment reduced the Tocky signal (reflecting engagement with cognate antigen), in both Treg and conventional subsets of CD4+, but not in CD8 +cells. However, a higher percentage of Treg than of conventional CD4 +maintained frequent engagement with antigens on treatment, reflecting a predominance of suppressive over effector function within the CD4 +compartment. The only T cell subset which correlated with a reduction in tumor growth was within Tocky signal positive conventional CD4+, supporting their therapeutic role. Targeting CD25 high, antigen-engaged Treg with a depleting anti-CD25 ICI, achieved complete cures in 100% of mice with triple therapy. Transcriptomic analysis confirmed reduction in Foxp3 on addition of anti-CD25 to HSV/BRAFi, as well as increases in expression of genes reflecting interferon signaling and cytotoxic activity.

CONCLUSIONS:

Combination HSV/BRAFi is an immunogenic therapy for BRAF mutant melanoma, but cannot fully control tumors. Dual therapy results in changes in T cell dynamics within tumors, with relatively maintained antigen signaling in Treg compared with conv CD4+. Antigen-engaged CD4 +effectors correlate with tumor growth control, and depletion of Treg by addition of an anti-CD25 ICI, releasing suppression of conventional CD4 +effectors by Treg, enhances survival and activates immune signaling within tumors.

• Authors: Galabina Bozhanova, Jehanne Hassan, Lizzie Appleton, Victoria Jennings, Shane Foo, Martin McLaughlin, Charleen Ml Chan Wah Hak, Emmanuel C Patin, Eva Crespo-Rodriguez, Gabby Baker, Edward Armstrong, Matthew Chiu, Hardev Pandha, Adel Samson, Victoria Roulstone, Joan Kyula, Richard Vile, Fiona Errington-Mais, Malin Pedersen, Kevin Harrington, Masahiro Ono, Alan Melcher
• Journal: Journal for immunotherapy of cancer (J Immunother Cancer) Vol. 10 Issue 3 (03 2022) ISSN: 2051-1426 [Electronic] England
• PMID: 35338089 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Chemical References

• Protein Kinase Inhibitors
• BRAF protein, human
• Proto-Oncogene Proteins B-raf

Topics

• Animals
• CD4-Positive T-Lymphocytes
• Herpes Simplex
• Humans
• Immunity
• Melanoma (drug therapy)
• Mice
• Mice, Inbred C57BL
• Oncolytic Viruses (physiology)
• Protein Kinase Inhibitors (therapeutic use)
• Proto-Oncogene Proteins B-raf (genetics)